Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.…
Veradermics to Present at the Jefferies Global Healthcare Conference in London
Could This Pill Be a Game Changer for Hair Loss? Veradermics Reports Major Breakthrough
Veradermics (NYSE: MANE) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 51 employees.
The shares were at 119.52 USD on 20 November 2026. Its 52-week range is 32.00 USD to 156.60 USD: the price is 23.7% below the high and 273.5% above the low.
Its market capitalisation is 5.04B USD.
Veradermics reports return on equity of -48.8% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 797.98M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 6 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 187.33 USD is 56.7% above the current price. The next earnings report is expected on 29 March 2027.